Products

Noventia Pharma is a company with a strong vocation for research, which develops and markets innovative products in various therapeutic areas.

The company has been focusing on production of increasingly more specific solutions, in particular for CNS and Oncology and secondarily for pathologies concerning ENT and Allergy.

Noventia Pharma offers through its organization two different lines of specialty prescription products, as well as Probiotics, Medical Food and Medical devices in a selected range of therapeutic areas .


Therapeutic areas:

» Neurology
» Pain Management
» Oncology
» Immunotherapy / Vaccines

 
Noentia Pharma also pays a lot of attention to patient treatment and assistance for those affected by rare and niche diseases offering to the medical and scientific communities new therapeutic options in treating such serious diseases.

 

 

 

 

RARE DISEASES

An orphan drug is a medicinal product developed for the treatment of a rare disease.

In Europe, the official definition of a rare disease is a disease affecting less than 5 per 10, 000 inhabitants, is fatal, or severely debilitating. Currently over 6000 rare diseases are known, which means that several million people are affected all over the world –over 25 million in Europe alone.

Today, treatment exists for only 200-300 of these 6000 diseases. Rare diseases are often genetic, meaning that newborns, children, and young adults often are affected. Physicians may never see a patient with a rare disease. For that reason there’s always a risk that when a baby is born with a rare disease, a correct diagnosis may not be made and appropriate treatment may not be given.

To provide care for these “forgotten patients” and to encourage pharmaceutical and biotechnology companies to invest in treatment for rare diseases, governments have created various legal and financial incentives. In 1983 the Orphan Drug Act was introduced in the US and in 1999 the “Regulation on orphan medicinal products” was approved by the European Parliament. This regulation grants, among other things, a ten-year market exclusivity for any new orphan drug.

Noventia  Pharma is committed to develop and provide Orphan Drugs for the treatment of Rare Diseases in particular for CNS (Wilson Disease patients).

One of our Company key point mission is the conviction that every patient has the right to the best possible treatment, especially patients suffering from a rare diseases